Palisade Bio is a clinical-stage biopharmaceutical company developing oral treatments for inflammatory bowel disease. Its sole active clinical asset is PALI-2108, a once-daily oral prodrug targeting ulcerative colitis and Crohn's disease, including fibrostenotic Crohn's disease, a fibrotic subtype with no currently approved pharmacologic treatments. PALI-2108 is a PDE4 inhibitor designed with a targeted activation mechanism: the drug remains inactive until it reaches the lower intestine, where gut bacteria convert it to its active form. This local activation aims to avoid the nausea and other side effects that have historically limited systemic PDE4 inhibitors. PALI-2108 is currently in Phase 1/1b trials in Canada; Palisade has completed dosing in healthy volunteers and a small UC patient cohort, and initiated a Phase 1b cohort in fibrostenotic Crohn's disease in late 2025. Palisade plans to submit IND applications to the FDA for Phase 2 studies in UC and Crohn's disease in 2026. The company has no revenue and funds operations through equity financing. Its path to returns involves advancing PALI-2108 through clinical trials toward either self-commercialization or out-licensing to a larger pharma partner. Palisade licensed its core technology from Giiant Pharma, to whom it owes milestone payments and future royalties. The company also retains residual legacy assets, including potential milestones from Alto Neuroscience, though these are unlikely to be material. Palisade has 14 full-time employees.